Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers

von Dutreix, Catherine, Munarini, Florence, Lorenzo, Sebastien, Roesel, Johannes, Wang, Yanfeng
Veröffentlicht 2013

Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin

von Barry, Elly V., Clark, Jennifer J., Cools, Jan, Roesel, Johannes, Gilliland, D. Gary
Veröffentlicht 2007

Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison

von Weisberg, Ellen, Roesel, Johannes, Furet, Pascal, Bold, Guido, Imbach, Patricia, Flörsheimer, Andreas, Caravatti, Georgio, Jiang, Jingrui, Manley, Paul, Ray, Arghya, Griffin, James D.
Veröffentlicht 2010

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors

von Levis, Mark, Brown, Patrick, Smith, B. Douglas, Stine, Adam, Pham, Rosalyn, Stone, Richard, DeAngelo, Daniel, Galinsky, Ilene, Giles, Frank, Estey, Elihu, Kantarjian, Hagop, Cohen, Pamela, Wang, Yanfeng, Roesel, Johannes, Karp, Judith E., Small, Donald
Veröffentlicht 2006

Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism

von Hitosugi, Taro, Fan, Jun, Chung, Tae-Wook, Lythgoe, Katherine, Wang, Xu, Xie, Jianxin, Ge, Qingyuan, Gu, Ting-Lei, Polakiewicz, Roberto D., Roesel, Johannes L., Chen, Zhuo (Georgia), Boggon, Titus J., Lonial, Sagar, Fu, Haian, Khuri, Fadlo R., Kang, Sumin, Chen, Jing
Veröffentlicht 2011

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth

von Peter, Barbara, Winter, Georg E., Blatt, Katharina, Bennett, Keiryn L., Stefanzl, Gabriele, Rix, Uwe, Eisenwort, Gregor, Hadzijusufovic, Emir, Gridling, Manuela, Dutreix, Catherine, Hoermann, Gregor, Schwaab, Juliana, Radia, Deepti, Roesel, Johannes, Manley, Paul W., Reiter, Andreas, Superti-Furga, Giulio, Valent, Peter
Veröffentlicht in Leukemia (2015)

Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation

von Kang, Sumin, Elf, Shannon, Dong, Shaozhong, Hitosugi, Taro, Lythgoe, Katherine, Guo, Ailan, Ruan, Hong, Lonial, Sagar, Khoury, Hanna J., Williams, Ifor R., Lee, Benjamin H., Roesel, Johannes L., Karsenty, Gerard, Hanauer, André, Taunton, Jack, Boggon, Titus J., Gu, Ting-Lei, Chen, Jing
Veröffentlicht 2009

Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells

von Weisberg, Ellen, Roesel, Johannes, Bold, Guido, Furet, Pascal, Jiang, Jingrui, Cools, Jan, Wright, Renee D., Nelson, Erik, Barrett, Rosemary, Ray, Arghya, Moreno, Daisy, Hall-Meyers, Elizabeth, Stone, Richard, Galinsky, Ilene, Fox, Edward, Gilliland, Gary, Daley, John F., Lazo-Kallanian, Suzan, Kung, Andrew L., Griffin, James D.
Veröffentlicht 2008

Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

von Hitosugi, Taro, Kang, Sumin, Vander Heiden, Matthew G., Chung, Tae-Wook, Elf, Shannon, Lythgoe, Katherine, Dong, Shaozhong, Lonial, Sagar, Wang, Xu, Chen, Georgia Z., Xie, Jianxin, Gu, Ting-Lei, Polakiewicz, Roberto D., Roesel, Johannes L., Boggon, Titus J., Khuri, Fadlo R., Gilliland, D. Gary, Cantley, Lewis C., Kaufman, Jonathan, Chen, Jing
Veröffentlicht 2009

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder

von Chen, Jing, DeAngelo, Daniel J., Kutok, Jeffery L., Williams, Ifor R., Lee, Benjamin H., Wadleigh, Martha, Duclos, Nicole, Cohen, Sarah, Adelsperger, Jennifer, Okabe, Rachel, Coburn, Allison, Galinsky, Ilene, Huntly, Brian, Cohen, Pamela S., Meyer, Thomas, Fabbro, Doriano, Roesel, Johannes, Banerji, Lolita, Griffin, James D., Xiao, Sheng, Fletcher, Jonathan A., Stone, Richard M., Gilliland, D. Gary
Veröffentlicht 2004